These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12807397)

  • 1. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
    Yasui K; Nakaso K; Kowa H; Takeshima T; Nakashima K
    Acta Neurol Scand; 2003 Jul; 108(1):66-7. PubMed ID: 12807397
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
    Müller T; Muhlack S
    Parkinsonism Relat Disord; 2010 Dec; 16(10):688-9. PubMed ID: 20719554
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum homocysteine and physical exercise in patients with Parkinson's disease.
    Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
    Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
    Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
    Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
    Di Rocco A; Werner P
    Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14981202
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
    Schroecksnadel K; Leblhuber F; Fuchs D
    Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14994447
    [No Abstract]   [Full Text] [Related]  

  • 8. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
    Müller T; Jugel C; Ehret R; Ebersbach G; Bengel G; Muhlack S; Klostermann F
    J Neural Transm (Vienna); 2011 Sep; 118(9):1329-33. PubMed ID: 21359971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
    Anamnart C; Kitjarak R
    J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
    Di Rocco A; Werner P
    Neurology; 2007 Apr; 68(17):1440; author reply 1440-1. PubMed ID: 17452598
    [No Abstract]   [Full Text] [Related]  

  • 11. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
    O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
    Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?
    Postuma RB; Lang AE
    Neurology; 2004 Sep; 63(5):886-91. PubMed ID: 15365141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
    Paul R; Borah A
    Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
    Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
    Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa elevates homocysteine: is this a problem?
    O'Suilleabhain P; Diaz-Arrastia R
    Arch Neurol; 2004 May; 61(5):633-4. PubMed ID: 15148136
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
    Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
    Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
    [No Abstract]   [Full Text] [Related]  

  • 18. The future of pharmacogenetics in Parkinson's disease treatment.
    Hutz MH; Rieder CR
    Pharmacogenomics; 2018 Feb; 19(3):171-174. PubMed ID: 29191064
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
    Ceravolo R; Cossu G; Bandettini di Poggio M; Santoro L; Barone P; Zibetti M; Frosini D; Nicoletti V; Manganelli F; Iodice R; Picillo M; Merola A; Lopiano L; Paribello A; Manca D; Melis M; Marchese R; Borelli P; Mereu A; Contu P; Abbruzzese G; Bonuccelli U
    Mov Disord; 2013 Sep; 28(10):1391-7. PubMed ID: 23836370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
    Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
    Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.